Metraipolis › archive › dc_656fdf55311c
Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy — Europe PMC PMID:41002573
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41002573
- DOI
- 10.3390/curroncol32090503
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T01:01:59.001Z
- SHA-256 of the archived text
bf1eff8534f3c912bd3773b91b77241bbdad2054325e4a97d962748b74112e81- Stable URL of this page
https://metraipolis.com/documento/dc_656fdf55311c
How to cite
Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy — Europe PMC PMID:41002573 — Europe PMC (en), https://europepmc.org/article/MED/41002573 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_656fdf55311c (Metraipolis archive dc_656fdf55311c, sha256 bf1eff8534f3c912bd3773b91b77241bbdad2054325e4a97d962748b74112e81)
BibTeX
@misc{dc656fdf55311c,
title = {Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy — Europe PMC PMID:41002573},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41002573},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_656fdf55311c; sha256 bf1eff8534f3c912bd3773b91b77241bbdad2054325e4a97d962748b74112e81},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41002573. Agents can read the archived copy with the MCP tool read_document.